Navigation Links
The Breast Cancer Therapeutics Market in Australia
Date:8/5/2009

SYDNEY, Aug. 5 /PRNewswire/ -- Rising public awareness of breast cancer and available treatments have increased revenues in the breast cancer therapeutics market in Australia. As the most common cancer diagnosed in Australia's female population, the total number of breast cancer patients in the country was 164,814 in 2008. This figure is estimated to reach 304,511 patients by 2013. Globally, breast cancer is second to lung cancer as the cause of death among women.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

Initiatives such as the BreastScreen Australia program, which provides free mammography services to aid in the early detection of breast cancer, have resulted in oncologists seeing more early stage disease. This, combined with aggressive and targeted therapy has, in turn, resulted in a reduction in the number of locally-advanced and metastatic breast cancer patients in the country.

The use of molecular targeted therapies as effective forms of cancer therapy is becoming more prevalent. These therapies are specifically designed to target cancer cells, while minimizing the adverse effects on normal cells when compared to cytotoxic chemotherapeutic drugs. New offerings must constitute therapies that will improve quality of life and survival rates if they are to thrive in this highly competitive market.

"Biopharmaceutical companies are placing more emphasis on developing targeted breast cancer therapies that offer patients not only increased efficacy, but reduced side effects as well," explains Carole Gaffud, Frost & Sullivan Research Analyst. "There are several new targeted therapies and chemotherapy drugs under development, including Epotheliones and Vascular Endothelial Growth Factor Receptor (VEGFR) inhibitors."

However
'/>"/>

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ImmunoVaccine Technologies Licenses Immunotopes Breast, Ovarian and Prostate Cancer Antigens
2. Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial
3. Monitoring Circulating Tumor Cells With the CellSearch(R) System Can Predict Prognosis in Metastatic Breast Cancer
4. New MRI technique could mean fewer breast biopsies in high-risk women
5. Genomic Health Reports Favorable Commentary on Value of Multigene Assays From the St. Gallen Expert Consensus Meeting on the Primary Treatment of Early Breast Cancer
6. Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer
7. DNA Genotek Partners with Roswell Park Cancer Institute to Accelerate Breast Cancer Research
8. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
9. Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting
10. Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting
11. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014  Discovery Laboratories, Inc. (Nasdaq: DSCO),  ... new standard of respiratory critical care, will report its ... 2014 before the open of the U.S. financial ... a live teleconference and webcast at 9:00 a.m. Eastern ... Discovery Labs, management will discuss the 2014 second ...
(Date:7/29/2014)... A new report by Allied ... and geography) - Size, Share, Global Trends, Company Profiles, ... 2013 - 2020", suggests that the global surgical equipment ... registering a CAGR of 11.1% from 2014 to 2020. ... electro surgical devices in operative procedures by providing highly ...
(Date:7/29/2014)... BEVERLY HILLS, Calif. , July 29, 2014 ... company specializing in personalized medicine, treatment of infectious ... developing strategies of prognosis and prevention of pathologies ...  As of August 1, 2014, ImmunoClin Corporation will ... to Washington, D.C. , a ...
(Date:7/29/2014)... & Rockville, MD (PRWEB) July 29, 2014 ... Inc. (ITI), a vaccine pioneer in the biotechnology ... services firm Newport Coast Securities, Inc. to explore ... is commercializing LAMP-vax technology, a breakthrough vaccine platform ... and immunotherapy market. The company exclusively licensed the ...
Breaking Biology Technology:Discovery Labs to Report 2014 Second Quarter Financial Results and Hold Conference Call on Tuesday, August 5, 2014 at 9:00 a.m. Eastern Time 2Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 2Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 3ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 2ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 3Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3
... Arbios Systems, Inc.,(OTC Bulletin Board: ABOS) today announced ... in its bioartificial liver system, HepatAssist, to HepaLife,Technologies, ... developing proprietary cell-based medical technologies to improve,protect and ... The terms of the deal included $450,000 in ...
... Patients Describe Their Life-Changing Results, CHAPEL HILL, ... classic "talk therapy" with a dynamic new set ... -- especially with,chronic health conditions such as pain, ... including Post Traumatic Stress Disorder (PTSD).,Known as "Energy ...
... Oct. 7, 2008 Senomyx, Inc.,(Nasdaq: SNMX ... taste,receptor technologies to discover and develop novel flavor ... announced today that,Kent Snyder, the Company,s President and ... and Business Officer, will present a,corporate overview on ...
Cached Biology Technology:Arbios Sells HepatAssist Bioartificial Liver System to HepaLife Technologies, Inc. 2Arbios Sells HepatAssist Bioartificial Liver System to HepaLife Technologies, Inc. 3Upcoming 'Energy Psychology' Event - New Breakthrough 'Do It Yourself' Healing 2SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE WACHOVIA CONSUMER GROWTH CONFERENCE 2
(Date:7/29/2014)... is the first to show that while the impact ... these negative effects may be reduced by maintaining a ... study participants who exercised, slept well and ate well ... maintain healthy lifestyles, even when they had similar levels ... professor in the department of psychiatry at UCSF. "It,s ...
(Date:7/28/2014)... Millions of people in the United States have a ... It can be painful and may even require surgery ... skeletal muscle wasting and, in turn, limb amputation. , ... Houston (UTHealth) Medical School, scientists tested a non-surgical preventative ... it was associated with increased blood circulation. Their ...
(Date:7/28/2014)... pennellii , a wild relative of the domestic tomato, ... including the labs headed by Professors Neelima Sinha and ... Biology. The new genome information may help breeders produce ... 27 in the journal Nature Genetics , was ... in Germany. The UC Davis labs carried out work ...
Breaking Biology News(10 mins):Healthy lifestyle may buffer against stress-related cell aging, study says 2Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2
... published online in the open-access journal PLoS Pathogens, Dr. ... colleagues identify new host species for avian influenza A ... between the ecology and epidemiology of various global strains ... included more than 36,000 wild migratory birds tested for ...
... of Missouri-Columbia has discovered a way to create engineered ... This discovery opens new possibilities for the development of ... bacteria and herbicides, and for the development of proteins ... illnesses. , In a paper published in the Proceedings ...
... genetic adaptations in the nematode Acrobeloides nanus. The ... more eggs under polluted conditions than the worms ... this in her study into the long-term effects ... Environmental pollution is an important cause of stress ...
Cached Biology News:Researchers attach genes to minichromosomes in maize 2Asexual worm quickly adapts to soil contamination 2
XBP-1 (F-4)...
Mouse monoclonal [AE3] to Cytokeratin 1 - 8, prediluted ( Abpromise for all tested applications). Antigen: Tissue / cell preparation - Human epidermal cells. Entrez GeneID: 140807 Swiss P...
pETDuet-1 is designed for the coexpression of two target genes....
...
Biology Products: